In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price target of Yen1,700.00. The company’s shares ...
Astellas signed a memorandum of agreement with Yaskawa in May 2024. Credit: yu_photo/Shutterstock. Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that ...
(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...
Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...
Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.
NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for ...
Ook opmerkelijk: veel meer koppels dan in 2014 werken nu ongeveer evenveel in deeltijd, wat bij 20 tot 35 uur per week het best zichtbaar is. Daar verdubbelde het aantal koppels ruim naar 292.000.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback